Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.

• Status: Unknown status
• Trial end date: 2020-01-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess efficacy of 10-day antimicrobial susceptibility test guided triple therapy for the first-line treatment of Helicobacter pylori infection, then comparing it with 14-day empirical tailored therapy to tell which one has a better performance in both efficacy and safety.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shandong University
• Treatments: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Bismuth; Clarithromycin; Furazolidone; Levofloxacin; Metronidazole; Ofloxacin; Pectin; Proton Pump Inhibitors; Tetracycline; Tinidazole

Criteria

Inclusion Criteria:

• Patients aged 18-70 with H. pylori infection.

Exclusion Criteria:

• Patients with previous H. pylori eradication therapy;

• Patients unable or unwilling to receive gastroscopy;

• Patients treated with H2-receptor antagonist, PPI, bismuth and antibiotics in the previous 4 weeks;

• Patients with gastrectomy, acute GI bleeding and advanced gastric cancer;

• Patients with known or suspected allergy to study medications;

• Currently pregnant or lactating;

• Inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.